Real-life long-term omalizumab therapy in children with severe allergic asthma

To the Editor:

We previously reported the French real-life experience of 1 year of add-on treatment with omalizumab in 101 severe allergic asthmatic children (6–18 years), 92 of whom were still receiving the treatment at the end of the first year [1]. The study provided complementary data to the previous randomised trials [2–6]. We showed a marked drop of 72% in the mean rate of severe exacerbations (from 4.4 per patient during the preceding year to 1.25 during the year of treatment) and of 88.5% for hospitalisations (44% of the patients during the preceding year to 6.7% during the year of treatment); a large improvement in asthma control (from 0% at initiation to 67% of well-controlled patients after 1 year); a decrease of 30% of the mean inhaled corticosteroid (ICS) dose (from 703 at initiation to 488 µg fluticasone equivalent per day after 1 year); and a forced expiratory volume in 1 s (FEV1) increase, from a mean of 88% to 92.1% of the predicted value. Treatment was discontinued in six patients due to serious adverse events attributed to omalizumab by the practitioner. Here we report the outcome of this cohort after 2 years of omalizumab treatment.

Outcome was assessed with the same criteria: rate of severe exacerbations, defined by requirement for systemic steroid bursts (>2 days) or hospitalisation; control, according to Global Initiative for Asthma (GINA) guidelines (apart from exacerbations), classified as uncontrolled, partially controlled or well controlled; ICS dose (µg fluticasone equivalent per day); and lung function (FEV1 and forced expiratory flow at 25–75% of forced vital capacity (FEF25–75%), both expressed as a percentage of the predicted value). Data are presented as frequencies and percentages for qualitative variables and as mean and 95% confidence interval for quantitative variables. Comparisons across the visits were performed by McNemar’s test for qualitative variables and by t-test for paired samples for quantitative variables. A p-value <0.05 was considered significant. All analyses were achieved with SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).

73 (79.3%) of the 92 children under treatment at the end of the first year were still receiving the treatment 2 years after initiation and were included in the analysis. Treatment was discontinued in 15 patients during the second year: four because of lack of health improvement, eight because of adverse events attributed to omalizumab, and three for personal reasons unrelated to the treatment. Four patients were lost to follow-up. The eight adverse events are displayed in table 1. Fatigue was reported in six patients and associated with erythema in one, local reactions in another, and an unexpected weight gain in a girl already overweight. General signs occurred in two patients and consisted of abdominal pain, headache and fever in one and haematuria, haemoptysis and arthralgia in the second, both resolved after discontinuing the drug.

At the end of the second year of treatment, we observed the maintenance of the benefits reported at 1 year in the children still receiving omalizumab. The severe exacerbation rate continued to decrease, reaching a mean (95% CI) of 0.22 (0.03–0.41) per year, −83% of the rate observed during the first year (p=0.0001) (fig. 1). No hospitalisation for exacerbation was recorded. We observed a nonsignificant improvement in the level of control, with 80% well-controlled, 15% partially controlled and 5% uncontrolled patients (p=0.17). At the end of the second year, the mean (95% CI) daily ICS dose remained unchanged at 429 (350–509) µg per day (p=1). No patient discontinued ICS treatment. However, 45 (63%) patients benefited from at least a 50% decrease in the initial dose of ICS. No additional gain in lung function was seen. At the end of 2 years of treatment, the FEV1 was 89.9% predicted (95% CI 86.7–93.0%) (p=0.38) and the FEF25–75% was 71.9% predicted (95% CI 65.7–78.0%) (p=0.98).

To the best of our knowledge, there are no specific paediatric data on omalizumab effectiveness beyond 1 year of administration. One adult study by PACE et al. [7] reported a marked improvement in clinical parameters and lung function in seven severe asthmatic patients after a 7-year course of omalizumab. In our study, we observed a persistent positive effect on the severe exacerbation rate, and a modest effect on asthma control in the children who continued omalizumab as add-on therapy. The lack of further lung function improvement despite a moderate to high ICS dose raises various hypotheses. The first is the compliance to treatment, which cannot be substantiated in our study as it was not formally evaluated. A second hypothesis is, as previously demonstrated, that FEV1 might not improve further in children with severe asthma [8]. However, modest improvement in FEV1 has been previously reported in clinical trials
In our cohort, FEV1 was stabilised at around 90% predicted, close to the expected value in controlled children, and this might be related to the disappearance of severe exacerbations [9].

Another main finding in our study is the high rate (20.7%) of omalizumab cessation during the second year. Besides treatment failure, patients’ own decisions and loss to follow-up, 8% of the patients stopped omalizumab because of side-effects, 75% of which were fatigue following injection. This was already reported during the first year of treatment but has not been reported in other studies [2–5, 10]. Two patients experienced generalised signs related to omalizumab, as they did not exist before initiating and disappeared after discontinuing the treatment (table 1) [10]. Although treatment has been reintroduced with success in one patient, these notifications warrant a careful long-term follow-up of treated children as delayed side-effects can happen. However, the whole benefit/risk ratio observed in this cohort favours the use of add-on treatment with omalizumab in severe allergic asthmatic children resistant to high-dose ICS as recently defined in the European Respiratory Society/American Thoracic Society Task Force [11] and GINA guidelines [12].

While the rationale for long-term treatment is supported by the pharmacokinetic-pharmacodynamic model described by Lowe and Riinard [13], the duration of omalizumab treatment is still under discussion. Our

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Weight (kg)</th>
<th>Total IgE (kU/L)</th>
<th>Treatment duration (months)</th>
<th>Dosage at discontinuation</th>
<th>Adverse event</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>13 years 9 months</td>
<td>49</td>
<td>1245</td>
<td>18</td>
<td>375 mg per 2 weeks</td>
<td>Fatigue</td>
<td>Resolution</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>11 years 4 months</td>
<td>35</td>
<td>1797</td>
<td>22</td>
<td>375 mg per 2 weeks</td>
<td>Fatigue</td>
<td>Resolution</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>15 years 9 months</td>
<td>80</td>
<td>572</td>
<td>13</td>
<td>375 mg per 2 weeks</td>
<td>Fatigue</td>
<td>Resolution</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>17 years 7 months</td>
<td>51</td>
<td>1796</td>
<td>23</td>
<td>375 mg per 2 weeks</td>
<td>Fatigue, local reaction</td>
<td>Resolution</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>15 years 8 months</td>
<td>82</td>
<td>139</td>
<td>18</td>
<td>300 mg per 4 weeks</td>
<td>Fatigue, erythema</td>
<td>Resolution</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>15 years 9 months</td>
<td>110</td>
<td>903</td>
<td>22</td>
<td>600 mg per 2 weeks</td>
<td>Fatigue, weight gain (8 kg in the first 6 months)</td>
<td>Resolution</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>13 years 1 month</td>
<td>39</td>
<td>550</td>
<td>13</td>
<td>150 mg per 4 weeks</td>
<td>Fever, abdominal pain, headache</td>
<td>Resolution</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>11 years 3 months</td>
<td>60</td>
<td>101</td>
<td>14</td>
<td>300 mg per 4 weeks</td>
<td>Haematuria, haemoptysis, arthralgia</td>
<td>Resolution</td>
</tr>
</tbody>
</table>

F: female; M: male. #: at the initiation of the treatment.

FIGURE 1 Change in exacerbation rates over a period of 104 weeks with add-on omalizumab treatment in children with uncontrolled severe allergic asthma. Data are presented as means with 95% confidence intervals.
real-life study suggests that omalizumab should be continued for >1 year. This is in accordance with the report of Molimard et al. [14], who analysed asthma control in 61 French patients (including 14 children) after discontinuation of omalizumab. Control was maintained for at least 6 months in 45% of the patients overall and 57% of the children. A treatment of longer than 3.5 years was associated with no loss of control during the following 6 months. Recently, the XPORT study evaluated the persistency of response to omalizumab in 176 adults with moderate to severe allergic asthma after long-term treatment (>3 years) [15]. Patients were randomised to continuation of omalizumab or withdrawal to placebo. At 1 year, 67% of the treated patients remained without exacerbation, compared with 47.7% in the placebo group.

All in all, the impact of omalizumab treatment on the natural history of severe asthma in children deserves to be further examined by long-term studies to define both the criteria and the timing for discontinuing the treatment. Adverse events should be carefully monitored and reported to pharmacovigilance units, with the aim of enhancing the knowledge of long-term omalizumab safety.

@ERSPublications
Beneficial effects at 2 years of omalizumab on severe exacerbations and control in severe allergic asthmatic children http://ow.ly/LGgnw

Antoine Deschildre1, Christophe Marguet2, Carole Langlois3, Isabelle Pin1, Jean-Luc Rittie4, Jocelyne Dereille6, Rola Abou Taam7, Michael Fayon8, Jacques Brouard9, Jean Christophe Dubus10, Daniel Siret11, Laurence Weiss12, Guillaume Pousselle13, Laurent Beghin14 and Jocelyne Just15,16,17

1Unité de pneumologie et allergologie pédiatriques, pôle enfant, clinique de pédiatrie Jeanne de Flandre, CHRU de Lille, Université Nord de France, Lille, France. 2Pédiatric respiratory disease and allergy unit, University Charles Nicolle Hospital, EA3830 GHRV, Rouen University, Rouen, France. 3Département de biostatistiques, CHRU de Lille, Université Nord de France, Lille, France. 4Pédiatrie, Pôle Couple Enfants, CHU de Grenoble, INSERM U823, Institut Albert Bonniot, Université Joseph Fourier, Grenoble, France. 5Allergologie – Pneumologie, Hôpital des Enfants, CHU Purpan Toulouse, Toulouse, France. 6Service de pédiatrie 1, Hôpital d’enfants de Brabois, CHU Nancy, Vandoeuvre-Lès-Nancy, France. 7Service de pneumologie et d’allergologie pédiatriques, hôpital Necker-Enfants-Malades, Paris, France. 8CHU de Bordeaux, Département de Pédiatrie, Centre d’Investigation Clinique (CIC 0005), Bordeaux, France. 9CHU de Caen, Dept of Pediatrics, Research unit EA 4655 U2RM, Caen, France. 10Unité de pneumologie et médecine infantile, CNRS, URMITE 6236, CHU Timone-Enfants, Aix-Marseille Université, Marseille, France. 11Service de Pédiatrie, CH de Saint-Nazaire, Saint-Nazaire, France. 12Pôle médico-chirurgical de Pédiatrie, CHU de Hautepiere, Strasbourg, France. 13Service de pédiatrie, CH Roubaix, Roubaix, France. 14CIC-9301-Inserm-CHU (Centre d’Investigation Clinique de Lille), CHRU de Lille and U995 Inserm, and Université Nord de France, Lille, France. 15Centre de l’Asthme et des Allergies, Hôpital des Enfants Armand-Trousseau, Paris, France. 16INSERM, UMR_S 1136, Sorbonne Universités, UPMC Université Paris 06, Paris, France. 17Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France.

Correspondence: Antoine Deschildre, Unité de pneumologie-allergologie pédiatrique, Clinique de pédiatrie Jeanne de Flandre, CHRU, 59037 Lille cedex, France. E-mail: antoine.deschildre@chru-lille.fr

Received: Jan 17 2015 | Accepted after revision: March 22 2015

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Support statement: This survey was funded by a grant from Novartis France and supported by the French Pediatric Pulmonology and Allergy Society (SP2A). Funding information for this article has been deposited with FundRef.

Acknowledgements: We are grateful to Céline Clairet (Centre d’Investigations Cliniques Pédiatriques, Lille University Hospital, Lille, France) for data collection and management.

References


